IL248590B - Adenovirus containing an albumin-binding group - Google Patents

Adenovirus containing an albumin-binding group

Info

Publication number
IL248590B
IL248590B IL248590A IL24859016A IL248590B IL 248590 B IL248590 B IL 248590B IL 248590 A IL248590 A IL 248590A IL 24859016 A IL24859016 A IL 24859016A IL 248590 B IL248590 B IL 248590B
Authority
IL
Israel
Prior art keywords
adenovirus
albumin
binding moiety
moiety
binding
Prior art date
Application number
IL248590A
Other languages
English (en)
Hebrew (he)
Other versions
IL248590A0 (en
Inventor
Bonastre Ramon Alemany
Exposito Luis Alfonso Rojas
Original Assignee
Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell
Inst Catala Doncologia Ico
Bonastre Ramon Alemany
Exposito Luis Alfonso Rojas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell, Inst Catala Doncologia Ico, Bonastre Ramon Alemany, Exposito Luis Alfonso Rojas filed Critical Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell
Publication of IL248590A0 publication Critical patent/IL248590A0/en
Publication of IL248590B publication Critical patent/IL248590B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL248590A 2014-04-30 2016-10-29 Adenovirus containing an albumin-binding group IL248590B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382162.7A EP2940128A1 (en) 2014-04-30 2014-04-30 Adenovirus comprising an albumin-binding moiety
PCT/EP2015/059593 WO2015166082A1 (en) 2014-04-30 2015-04-30 Adenovirus comprising an albumin-binding moiety

Publications (2)

Publication Number Publication Date
IL248590A0 IL248590A0 (en) 2016-12-29
IL248590B true IL248590B (en) 2021-01-31

Family

ID=50774820

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248590A IL248590B (en) 2014-04-30 2016-10-29 Adenovirus containing an albumin-binding group

Country Status (12)

Country Link
US (3) US10604549B2 (OSRAM)
EP (2) EP2940128A1 (OSRAM)
JP (1) JP6639412B2 (OSRAM)
KR (1) KR102628234B1 (OSRAM)
CN (1) CN106471125B (OSRAM)
AU (1) AU2015254535B2 (OSRAM)
BR (1) BR112016025297B1 (OSRAM)
CA (1) CA2946650C (OSRAM)
IL (1) IL248590B (OSRAM)
MX (1) MX381286B (OSRAM)
RU (1) RU2711371C2 (OSRAM)
WO (1) WO2015166082A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP2020530453A (ja) 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー アルブミン結合ペプチド結合体及びその方法
US20200330581A1 (en) * 2017-10-09 2020-10-22 Keith Black Oncolytic cancer immunotherapies and methods of use
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
EP3775175A4 (en) 2018-04-09 2022-02-09 Salk Institute for Biological Studies ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH IMPROVED REPLICATION PROPERTIES
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
KR102686295B1 (ko) 2018-11-21 2024-07-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 아데노바이러스 및 아데노바이러스의 사용 방법
CN113710694A (zh) 2019-04-29 2021-11-26 梅奥医学教育及研究基金会 用于治疗癌症的多价pd-l1结合化合物
CN114423860A (zh) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 包含病毒载体的细胞组合物及治疗方法
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
KR20230046298A (ko) 2020-08-10 2023-04-05 메조블라스트 인터내셔널 에스에이알엘 세포 조성물 및 치료 방법
WO2023109740A1 (zh) * 2021-12-13 2023-06-22 康希诺生物股份公司 一种重组腺病毒载体疫苗吸入给药递送系统
CN114159556B (zh) * 2021-12-14 2023-06-16 中国人民解放军军事科学院军事医学研究院 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体
WO2023120762A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
KR20230095830A (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
CN115624524B (zh) * 2022-10-25 2023-10-27 中国医科大学附属第一医院 Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CA2921260A1 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP4744771B2 (ja) * 2000-05-26 2011-08-10 大日本住友製薬株式会社 副作用を軽減した新規な組換えアデノウイルスベクター
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
HRP20100228T1 (hr) 2006-04-28 2010-07-31 The Trustees Of The University Of Pennsylvania Modificirani hekson protein adenovirusa i njegove uporabe
SG183044A1 (en) 2007-07-16 2012-08-30 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2558481B1 (en) 2010-04-14 2017-12-20 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use

Also Published As

Publication number Publication date
US10604549B2 (en) 2020-03-31
US20230331786A1 (en) 2023-10-19
EP2940128A1 (en) 2015-11-04
RU2016146664A3 (OSRAM) 2018-06-28
US20170051022A1 (en) 2017-02-23
EP3137599A1 (en) 2017-03-08
BR112016025297B1 (pt) 2022-08-30
JP6639412B2 (ja) 2020-02-05
MX2016014187A (es) 2017-05-03
MX381286B (es) 2025-03-12
IL248590A0 (en) 2016-12-29
RU2016146664A (ru) 2018-05-30
US20200181208A1 (en) 2020-06-11
CA2946650A1 (en) 2015-11-05
RU2711371C2 (ru) 2020-01-16
CN106471125A (zh) 2017-03-01
CN106471125B (zh) 2021-04-06
AU2015254535B2 (en) 2020-08-13
AU2015254535A1 (en) 2016-12-01
BR112016025297A2 (pt) 2017-10-17
CA2946650C (en) 2023-07-11
KR20160145825A (ko) 2016-12-20
KR102628234B1 (ko) 2024-01-22
JP2017514483A (ja) 2017-06-08
WO2015166082A1 (en) 2015-11-05
US11578104B2 (en) 2023-02-14

Similar Documents

Publication Publication Date Title
IL304663A (en) combination
IL248590B (en) Adenovirus containing an albumin-binding group
IL247073A0 (en) combination
EP3981335C0 (en) BIOPSY DEVICE
PT3122358T (pt) Combinações de inibidores do fgfr e cmet para o tratamento do cancro
IL248707A0 (en) Integral dual gimbal device
GB201412161D0 (en) Structure
GB2528078B (en) Structure
SG11201608628WA (en) Propulsion unit
GB2522522B (en) Structure
GB201419861D0 (en) Mount
GB201505423D0 (en) Not published
DK3177838T3 (en) Fluid-redirecting structure
GB2541830B (en) Positioning Unit
TWI560126B (en) Positioning mechanism
GB201402083D0 (en) Retaining means
PT2902216T (pt) Unidade funcional
GB201517502D0 (en) Positioning means
GB201414421D0 (en) Techflush unit
GB201504302D0 (en) Selfweigh mechanism
GB2537506B (en) Retaining mechanism
GB201401159D0 (en) Adenovirus
GB201420332D0 (en) Power-bet blackjack
GB201402240D0 (en) Antiseptics
AU366104S (en) 16Amp Mechanism

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed